-
货号
KDC82803
-
描述
PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Human TFPI has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Marstacimab in the sample competitively binds to the pre-coated protein with biotin-labeled Marstacimab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Marstacimab bound in the initial step. The color development is stopped and the intensity of the color is measured.
-
应用
Used for the quantitative determination of Marstacimab concentration in serum and plasma. -
检测方法
Colorimetric -
样本类型
Plasma, Serum -
实验类型
Quantitative -
检测范围
31.25 - 1,000 ng/mL -
灵敏度
39.99 ng/mL -
精准度
Intra-Assay Precision (Precision within an assay): <20%
Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): <20%
Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.
Intra-Assay Precision
Inter-Assay Precision
Sample
1
2
3
1
2
3
n
16
16
16
24
24
24
Mean (ng/mL)
574.2
120.8
47.5
463.0
118.3
46.5
Standard deviation
50.2
12.8
8.1
33.1
14.9
9.3
CV (%)
8.7
10.6
17.1
7.2
12.6
19.9
-
回收率
80-120% -
运输
2-8 ℃ -
稳定性和存储
When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. -
别名
PF-06741086, CAS: 1985638-39-8
-
背景
Marstacimab, previously known as PF-06741086, is a fully human monoclonal antibody IgG1 antibody that binds to the K2 domain of TFPI at nanomolar to suprananomolar concentration ranges. Non-clinical experiments demonstrated that marstacimab could enhance thrombin generation in vitro and in vivo in a concentration-dependent manner. In vitro thrombin generation assays (TGAs) and dilute prothrombin time (dPT) assays evaluating Marstacimab added to donor plasma from healthy normal volunteers and patients with haemophilia A, haemophilia B, and haemophilia A with inhibitors have all shown the ability of marstacimab to increase coagulation activity and promote haemostasis. Bleed control was demonstrated in severe injury mice models of haemophilia A and B.
